前列腺动脉化疗栓塞治疗局限性晚期前列腺癌患者难治性血尿和尿潴留
研究评估经导管动脉化疗栓塞(TACE)治疗局限性晚期前列腺癌相关难治性肉眼血尿(RGH)和尿潴留(UR)的安全性与疗效。32例患者接受表柔比星洗脱HepaSpheres联合动脉内多西他赛输注,技术成功率为100%,无严重不良事件。TACE后所有患者RGH在5天内停止,26例(86.7%)在平均24个月随访中出血控制良好;22例UR患者中17例(77.3%)恢复自主排尿,15例(88.2%)末次随访时无需导尿管。
要点
- TACE技术成功率为100%,无严重不良事件发生。
- TACE后所有患者肉眼血尿在5天内停止,26例(86.7%)在平均24个月随访中出血控制良好。
- 22例尿潴留患者中17例(77.3%)恢复自主排尿,15例(88.2%)末次随访时无需导尿管。
核心结论
- 使用表柔比星洗脱HepaSpheres联合动脉内多西他赛输注的TACE是晚期前列腺癌伴肉眼血尿和尿潴留患者安全有效的治疗选择,若无其他治疗选择时可考虑作为替代方案。
研究设计与样本
- 纳入32例(平均年龄72.5岁,范围60-89岁)晚期前列腺癌相关难治性肉眼血尿且常规治疗失败的患者,其中22例因前列腺癌相关尿潴留而依赖导尿管。
- TACE采用表柔比星洗脱HepaSpheres联合动脉内多西他赛输注,评估技术成功、不良事件、总生存、肉眼血尿控制、导尿管拔除及局部疾病控制。
主要发现
- 技术成功率为100%,无严重不良事件;TACE后平均随访27个月(范围8-56个月),平均总生存30个月。
- 所有患者肉眼血尿在TACE后5天内停止,26例(86.7%)在平均24个月随访中出血控制良好。
- 22例尿潴留患者中17例(77.3%)恢复自主排尿,15例(88.2%)在平均24个月末次随访时无需导尿管。
- 平均随访29个月时,73.3%(22/30)患者获得活检阴性结果;末次访视时22例平均随访36个月,前列腺体积平均缩小55.5%,与基线相比差异有统计学意义(P = 0.022)。
- TACE后12-47个月,84.2%(16/19)患者活检结果为阴性;与基线相比,IPSS、QoL、Qmax和PVR均显著改善(均P < 0.05)。
临床怎么用
- 作者认为,对于晚期前列腺癌伴肉眼血尿和尿潴留且无其他治疗选择时,可考虑使用表柔比星洗脱HepaSpheres联合动脉内多西他赛输注的TACE作为替代方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the safety and efficacy transcatheter arterial chemoembolization (TACE) for the treatment of refractory gross hematuria (RGH) and urinary retention (UR) secondary to localized advanced prostate cancer (PCa). PATIENTS AND METHODS: Thirty-two patients (mean age 72.5 years, range 60-89) with advanced PCa-related RGH that failed conventional therapy were included. Twenty-two of these patients had catheter-dependent due to PCa-related UR. TACE was performed with epirubicin (EPI)-eluting HepaSpheres (HS) plus intra-arterial (IA) infusion of docetaxel. Technical success, adverse events (AEs), overall survival (OS), control of RGH, removal of indwelling catheters, and local disease control, were evaluated. RESULTS: Technical success was achieved in 100% without major AEs. Mean follow up post-TACE was 27 months (range 8-56 months) with a mean OS of 30 months. GRH stopped within 5 days after TACE in all patients, 26 (86.7%) of these patients exhibited good bleeding control during a mean follow-up of 24 months; 17 (77.3%) of the 22 patients with UR had recovered spontaneous urination, 15 (88.2%) patients were catheter-free at their last follow-up with a mean of 24 months. BS was obtained in 73.3% (22/30) of patients at a mean follow-up of 29 months. At the last visit, 22 patients had a mean of 36 months follow-up and the mean percentage reduction in prostate volume was 55.5%, with a statistically different from baseline (P = 0.022). Negative biopsy results were obtained in 84.2% (16/19) of the patients at 12-47 months after TACE. Compared with baseline values, there was a significant improvements in IPSS, QoL, Qmax, and PVR (all P < 0.05). CONCLUSIONS: TACE using EPI-eluting HS plus IA infusion of docetaxel is a safe and effective treatment option for the advanced PCa patients with GRH and UR, and it could be considered as an alternative if there was no other therapeutic choice.
引用
- Wang MQ, Zhang JL, Duan F, et al. Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 35249108. doi:10.1038/s41391-022-00516-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。